Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, March 2002, p. 646-653, Vol. 46, No. 3
0066-4804/02/$04.00+0 DOI: 10.1128/AAC.46.3.646-653.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Departments of Biochemistry and Molecular Biology,1 Medicine, Wayne State University, Detroit, Michigan 48201,2 Department of Chemistry, Wayne State University, Detroit, Michigan 482023
Received 17 May 2001/ Returned for modification 23 September 2001/ Accepted 23 November 2001
A derivative of the TEM-1 ß-lactamase producing clinically significant levels of resistance to ceftazidime and ß-lactamase inhibitors in the presence of penicillins was generated following five rounds of DNA shuffling and selection. This complex mutant enzyme contained three amino acid substitutions including those of residues 104 and 276 that are known to produce extended-spectrum resistance and, correspondingly, resistance to ß-lactamase inhibitors. Although the Glu104Lys substitution by itself produced low levels of ceftazidime resistance, additional amino acid replacements in the enzyme with the triple mutation resulted in further enhancement of resistance to ceftazidime. Kinetic studies of the purified ß-lactamase enzyme with the triple mutation indicated enhancement of the catalytic efficiency for turnover (kcat/Km) of ceftazidime. The increases in the Ki values of both clavulanic acid and tazobactam for the enzyme with the triple mutation were consistent with the observed bacterial resistance to the reversibility of ß-lactam resistance with these inhibitors.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»